Reprogramming of glucose metabolism: Metabolic alterations in the progression of osteosarcoma

被引:6
作者
An, Fangyu [1 ]
Chang, Weirong [2 ]
Zhang, Jie [2 ]
Li, Zhonghong [1 ]
Gao, Peng [2 ]
Wang, Yujie [3 ]
Xiao, Zhipan [3 ]
Yan, Chunlu [3 ]
机构
[1] Gansu Univ Chinese Med, Teaching Expt Training Ctr, Lanzhou 730000, Gansu, Peoples R China
[2] Gansu Univ Chinese Med, Sch Basic Med, Lanzhou 730000, Gansu, Peoples R China
[3] Gansu Univ Chinese Med, Sch Tradit Chinese & Western Med, Lanzhou 730000, Gansu, Peoples R China
关键词
Osteosarcoma; Glucose metabolism; Key enzymes; Signaling pathways; Targeted therapy; CANCER-CELL-PROLIFERATION; IN-VITRO; LACTATE-DEHYDROGENASE; AEROBIC GLYCOLYSIS; GROWTH; PROMOTES; PATHWAY; APOPTOSIS; METASTASIS; EXPRESSION;
D O I
10.1016/j.jbo.2024.100521
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Metabolic reprogramming is an adaptive response of tumour cells under hypoxia and low nutrition conditions. There is increasing evidence that glucose metabolism reprogramming can regulate the growth and metastasis of osteosarcoma (OS). Reprogramming in the progress of OS can bring opportunities for early diagnosis and treatment of OS. Previous research mainly focused on the glycolytic pathway of glucose metabolism, often neglecting the tricarboxylic acid cycle and pentose phosphate pathway. However, the tricarboxylic acid cycle and pentose phosphate pathway of glucose metabolism are also involved in the progression of OS and are closely related to this disease. The research on glucose metabolism in OS has not yet been summarized. In this review, we discuss the abnormal expression of key molecules related to glucose metabolism in OS and summarize the glucose metabolism related signaling pathways involved in the occurrence and development of OS. In addition, we discuss some of the targeted drugs that regulate glucose metabolism pathways, which can lead to effective strategies for targeted treatment of OS.
引用
收藏
页数:15
相关论文
共 50 条
  • [41] Progression-Dependent Altered Metabolism in Osteosarcoma Resulting in Different Nutrient Source Dependencies
    Fritsche-Guenther, Raphaela
    Gloaguen, Yoann
    Kirchner, Marieluise
    Mertins, Philipp
    Tunn, Per-Ulf
    Kirwan, Jennifer A.
    CANCERS, 2020, 12 (06)
  • [42] Stromal epigenetic alterations drive metabolic and neuroendocrine prostate cancer reprogramming
    Mishra, Rajeev
    Haldar, Subhash
    Placencio, Veronica
    Madhav, Anisha
    Rohena-Rivera, Krizia
    Agarwal, Priyanka
    Duong, Frank
    Angara, Bryan
    Tripathi, Manisha
    Liu, Zhenqiu
    Gottlieb, Roberta A.
    Wagner, Shawn
    Posadas, Edwin M.
    Bhowmick, Neil A.
    JOURNAL OF CLINICAL INVESTIGATION, 2018, 128 (10) : 4472 - 4484
  • [43] P2RX7 promotes osteosarcoma progression and glucose metabolism by enhancing c-Myc stabilization
    Gaohong Sheng
    Yuan Gao
    Qing Ding
    Ruizhuo Zhang
    Tianqi Wang
    Shaoze Jing
    Hongqi Zhao
    Tian Ma
    Hua Wu
    Yong Yang
    Journal of Translational Medicine, 21
  • [44] Linking Metabolic Reprogramming, Plasticity and Tumor Progression
    Shuvalov, Oleg
    Daks, Alexandra
    Fedorova, Olga
    Petukhov, Alexey
    Barlev, Nickolai
    CANCERS, 2021, 13 (04) : 1 - 25
  • [45] Exosome-mediated metabolic reprogramming: Implications in esophageal carcinoma progression and tumor microenvironment remodeling
    Xi, Yong
    Shen, Yaxing
    Chen, Lijie
    Tan, Lijie
    Shen, Weiyu
    Niu, Xing
    CYTOKINE & GROWTH FACTOR REVIEWS, 2023, 73 : 78 - 92
  • [46] Pramlintide: A Novel Therapeutic Approach for Osteosarcoma through Metabolic Reprogramming
    Yang, Yuanzheng
    Peng, Zhanglong
    Flores, Elsa R.
    Kleinerman, Eugenie S.
    CANCERS, 2022, 14 (17)
  • [47] Lipid metabolic reprogramming and associated ferroptosis in osteosarcoma: From molecular mechanisms to potential targets
    Yin, Zhiyang
    Shen, Guanlu
    Fan, Minjie
    Zheng, Pengfei
    JOURNAL OF BONE ONCOLOGY, 2025, 51
  • [48] Genetic and clonal dissection of osteosarcoma progression and lung metastasis
    Xu, Huaiyuan
    Zhu, Xiaojun
    Bao, Hua
    Shek, Tony Wh
    Huang, Zongwen
    Wang, Yongqian
    Wu, Xue
    Wu, Yong
    Chang, Zhili
    Wu, Shuyu
    Tang, Qinglian
    Zhang, Huizhong
    Han, Anjia
    Mc Cheung, Kenneth
    Zou, Changye
    Yau, Raymond
    Ho, Wai-Yip
    Huang, Gang
    Batalha, Sellma
    Lu, Jinchang
    Song, Guohui
    Kang, Yao
    Shao, Yang W.
    Lam, Ying Lee
    Shen, Jingnan
    Wang, Jin
    INTERNATIONAL JOURNAL OF CANCER, 2018, 143 (05) : 1134 - 1142
  • [49] Research progress in the metabolic reprogramming of hepatocellular carcinoma (Review)
    Gao, Wenyue
    Wang, Jing
    Xu, Yuting
    Yu, Hongbo
    Yi, Sitong
    Bai, Changchuan
    Cong, Qingwei
    Zhu, Ying
    MOLECULAR MEDICINE REPORTS, 2024, 30 (01)
  • [50] Molecular alterations as target for therapy in metastatic osteosarcoma: a review of literature
    PosthumaDeBoer, J.
    Witlox, M. A.
    Kaspers, G. J. L.
    van Royen, B. J.
    CLINICAL & EXPERIMENTAL METASTASIS, 2011, 28 (05) : 493 - 503